title: Anosmin-1 modulates the FGF-2-dependent migration of oligodendrocyte precursors in the developing optic nerve.
abstract: Oligodendrocyte precursors (OPCs) originate at specific domains within the neural tube before migrating to colonize the entire CNS. Once in their target areas, these cells differentiate into oligodendrocytes, the myelin-forming cells in the CNS. Using the embryonic mouse optic nerve as an experimental model, we have analyzed the influence of FGF-2 on OPC development. FGF-2 exerts a dose-dependent motogenic effect on the migration of plp-dm20+ and it also acts as a chemoattractant on these cells. These effects produced by FGF-2 are principally mediated by the FGFR1 receptor, which is expressed by OPCs. Anosmin-1 is the protein that is defective in the X-linked form of human Kallmann syndrome. This protein is expressed by retinal axons and it also interacts with FGFR1, thereby impairing the migration of OPCs. Because both Anosmin-1 and FGF-2 are present in the optic nerve in vivo, we propose a model whereby the relative concentration of these two proteins modulates the migration of OPCs during development through their interaction with FGFR1. This FGF-2/FGFR1/Anosmin-1 system may be relevant in the context of demyelinating diseases.
authors.affiliation: Instituto de Neurociencias de Castilla y León-INCyL, Universidad de Salamanca, Avda. de Alfonso X el Sabio, s/n, E-37007-Salamanca, Spain.
authors.forename: Ana
authors.initials: A
authors.lastname: Bribián
authors.forename: María José
authors.initials: MJ
authors.lastname: Barallobre
authors.forename: Nadia
authors.initials: N
authors.lastname: Soussi-Yanicostas
authors.forename: Fernando
authors.initials: F
authors.lastname: de Castro
mesh_terms: D000818:Animals; D002454:Cell Differentiation; D002465:Cell Movement / Q000502:physiology*; D002478:Cells, Cultured; D002630:Chemotactic Factors / Q000378:metabolism / Q000494:pharmacology; D017077:Culture Media, Conditioned / Q000737:chemistry; D016326:Extracellular Matrix Proteins / Q000235:genetics / Q000378:metabolism*; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism / Q000494:pharmacology*; D040181:Genetic Diseases, X-Linked / Q000378:metabolism; D006801:Humans; D017436:Kallmann Syndrome / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D009419:Nerve Tissue Proteins / Q000235:genetics / Q000378:metabolism*; D009836:Oligodendroglia / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D009900:Optic Nerve / Q000166:cytology / Q000196:embryology; D051381:Rats; D017208:Rats, Wistar; D051496:Receptor, Fibroblast Growth Factor, Type 1 / Q000378:metabolism; D012160:Retina / Q000166:cytology / Q000196:embryology / Q000378:metabolism; D013234:Stem Cells / Q000166:cytology / Q000187:drug effects* / Q000502:physiology
chemical_list: C076266:ANOS1 protein, human; D002630:Chemotactic Factors; D017077:Culture Media, Conditioned; D016326:Extracellular Matrix Proteins; D009419:Nerve Tissue Proteins; D016222:Fibroblast Growth Factor 2; D051496:Receptor, Fibroblast Growth Factor, Type 1